The AML Content Hub Channel

45:42

The Use of Intensive Treatment in Elderly Patients With AML

AML Content Hub

@GOssenkoppele discusses #AML treatment in #elderly patients.

6:39

Treating AML After Evolution From MPD

AML Content Hub

Raajit K. Rampal, MD, PhD, of @sloankettering, discusses #treatment for patients with #AML which has evolved from #myeloproliferative disease.

2:48

Emerging AML Therapies 2025

AML Content Hub

Naval G. Daver, MD, a professor and director of the Leukemia Research Alliance Program, MD Anderson Cancer Center, Houston, Texas, highlighted significant advancements in acute myeloid leukemia (AML)…

5:38

Challenges Faced by Patients With AML in Complete Remission

AML Content Hub

At #EBMT2021, Norbert Vey, MD, of @paoli_calmettes, discusses #challenges faced by patients with #AML in #CompleteRemission.

2:14

Dr. Daver on the Utility of Maintenance Therapy in AML

AML Content Hub

Naval G. Daver, MD, an associate professor in the Department of Leukemia, Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center, discusses maintenance chemotherapy…

1:17

Treatment Landscape for Acute Myeloid Leukemia Appears Hopeful for Patients

AML Content Hub

Eunice Wang, MD, chief of the Leukemia Service at the Roswell Park Comprehensive Cancer Center, discusses the outlook of acute myeloid leukemia (AML) treatment in the wake of…

19:01

Managing Relapsed FLT3+ AML

AML Content Hub

In this video, Naval G. Daver, MD, a professor and director of the Leukemia Research Alliance Program, MD Anderson Cancer Center, Houston, Texas, and Uma Borate, MBBS, Acute…

1:44

FLT3 Inhibitors for Managing Patients With AML

AML Content Hub

Alexander Perl, MD, University of Pennsylvania, Philadelphia, PA, reviews the role of FLT3 inhibitors for treating patients with FLT3-mutated acute myeloid leukemia. Dr Perl discusses how FLT3 inhibitors…

3:55

Targeted Therapy for Acute Myeloid Leukemia

AML Content Hub

Eunice Wang, MD, Chief of the Leukemia Service at Roswell Park Comprehensive Cancer Center, describes acute myeloid leukemia (AML) and details how emerging targeted treatments are transforming the…

1:23

Challenges for Physicians and Patients With AML During the COVID-19 Pandemic

AML Content Hub

Andrew Krivoshik, MD, PhD, Oncology Therapeutic Area Head at Astellas Pharma, discusses acute myeloid leukemia (AML) in the context of the COVID-19 pandemic. The prevalence of healthcare disparities…

2:36

Earlier AML Detection

AML Content Hub

@DrChrisHourigan, from @nih_nhlbi, discusses earlier #AML #detection and #measurable #residual #disease.

1:11

Dr. Talati on the Rationale for Venetoclax in AML

AML Content Hub

Phase 3 Clinical Trials Using Venetoclax for the Treatment of Acute Myeloid Leukemia

:58

Dr. Mesa on Racial Disparities in MPN, MDS, and AML Clinical Trials

AML Content Hub

Ruben A. Mesa, MD, director of the Mays Cancer Center at UT Health San Antonio MD Anderson Cancer Center, discusses barriers to achieving racially diverse clinical trials for…

1:26

Selecting Intensive Therapy in Younger Patients With AML

AML Content Hub

Amir Fathi, MD, MPH, Massachusetts General Hospital, Boston, MA, discusses current therapeutic options for younger patients with acute myeloid leukemia. Dr Fathi notes that the approved guidance for…

22:15

Infection Prevention Strategies in AML

AML Content Hub

In a presentation at the 2024 International Pathology Day virtual conference, Dr Justin Loke, CRUK/AACR Transatlantic Fellow, University of Birmingham, UK and Dana-Farber Cancer Institute, USA, explains how…

2:19

Horizon of Targeted Molecular Therapies for Acute Myeloid Leukemia Presented at ASH 2020 Conference

AML Content Hub

Thomas Prebet, MD, PhD, Yale School of Medicine, previews recent advancements and treatment options for acute myeloid leukemia (AML) patients with TP53, IDH, and FLT3 mutations. Dr. Prebet…

Dr. DiNardo Discusses VIALE-A and Venetoclax Combo in AML

AML Content Hub

Courtney DiNardo, MD, MSCE, clinical researcher in the Department of Leukemia of the Division of Cancer Medicine at the University of Texas MD Anderson Cancer Center, presents promising…

4:46

AML Highlights From EHA 2025

AML Content Hub

In an interview conducted at the 30th Congress of the European Hematology Association (EHA) in Milan, Italy, Gail J. Roboz, MD, professor of medicine and director of the…

Expert Discusses Novel Treatment Approach for TP53-Mutant MDS and AML

AML Content Hub

Raajit K. Rampal, MD, PhD, hematologic oncologist at Memorial Sloan Kettering Cancer Center, discusses a recent study on the use of APR-246 for the treatment of myelodysplastic syndrome…

3:15

The Impact of Molecular Testing on Treatment Options for AML

AML Content Hub

David Sallman, MD, of @MoffittNews, discusses #moleculartesting for #AML.

21:28

Highlights From the 7th International Workshop on Acute Leukemias

AML Content Hub

Harry Erba, MD, PhD, Duke University, Durham, NC; Marina Konopleva, MD, PhD, Albert Einstein College of Medicine, New York City, NY; Thomas Cluzeau, MD, PhD, Central University Hospital…

31:30

Minimal Residual Disease in Hematologic Malignancies: Testing Considerations and Challenges

AML Content Hub

In this webcast symposium, Gail J. Roboz, MD, professor of medicine and director of the Clinical and Translational Leukemia Program at the Weill Medical College of Cornell University…

1:22

The Immunological Impact of TP53 in Patients With MDS

AML Content Hub

@ShahramKordasti, of @KingsCollegeLon, discusses the #immunological impact of TP53 mutations on #MDS #prognosis.

1:44

Beat AML: Clinical Trial Insights

AML Content Hub

In this update, Ashley Yocum, PhD, executive research strategy lead of the Beat AML Master Trial at the Leukemia & Lymphoma Society, provides insights into the Beat AML…

AML Guideline Reinforces Individualized Treatment

AML Content Hub

Guidelines from the American Society of Hematology (ASH) review panel recommend standards of care for individualized acute myeloid leukemia (AML) treatments. For patients with newly diagnosed AML, ASH…

2:12

Allogeneic Stem Cell Transplantation for Patients With Refractory AML

AML Content Hub

@Mohty_EBMT discusses long-term survival in patients with refractory #AML using allo-SCT at #EBMT21

56:57

New Horizons in AML Treatment

AML Content Hub

Alice S. Mims, MD, of The Ohio State University’s James Comprehensive Cancer Center, provided an overview of current AML treatment options, such as FLT3 and IDH inhibitors, while…

2:42

Emerging Therapies for MDS

AML Content Hub

Felicitas Thol, MD, Hannover Medical School, Hannover, Germany, discusses #emergingtherapies for #MDS.

25:27

Modern Approaches to AML Care

AML Content Hub

In this presentation, Anand A. Patel, MD, reviewed the contemporary standard-of-care treatment roadmap for AML in 2025, covering key phases like induction chemotherapy (eg, the “7+3” regimen), consolidation…

Novel Strategies and Agents Emerge in AML Paradigm

AML Content Hub

Rebecca L. Olin, MD, MSCE, associate professor in the Department of Medicine at the University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center, discusses changes in…

1:38

Early Referrals for Transplantation May Improve Overall Survival in Older Patients with Myelodysplastic Syndrome

AML Content Hub

Corey Cutler, MD, MPH, medical director of the Adult Stem Cell Transplantation Center at Dana-Farber Cancer Institute, discusses Blood and Marrow Clinical Trials Network Study 1102, comparing patients…

2:04

Genetic Testing Expands Therapeutic Treatment Options for Acute Myeloid Leukemia Patients

AML Content Hub

Andrew Krivoshik, MD, PhD, Oncology Therapeutic Area Head at Astellas Pharma, reviews treatment options for acute myeloid leukemia (AML) patients. Dr. Krivoshik states that, while patients traditionally receive…

:42

Tomivosertib Exhibits Potent Anti-leukemic Properties on AML Cells

AML Content Hub

Researchers from @LurieCancer and @nufeinbergmed present anti-leukemic properties of #tomivosertib as #therapy for #AML.

7:02

Venetoclax-based Regimens for Select Patients With AML

AML Content Hub

James Foran, MD, of @MayoClinic, discusses key considerations for using #venetoclax in certain patients with #AML.

4:35

Considerations for Treatment Decision-Making in AML

AML Content Hub

David Sallman, MD, of @MoffittNews, discusses key considerations related to #treatmentselection in #AML.

Christopher Hourigan, DM, DPhil, on Mutation-based MRD and Conditioning for AML

AML Content Hub

Christopher Hourigan, MD, PhD, associate professor at Johns Hopkins and principal investigator at the National Heart, Lung, and Blood Institute of the National Institutes of Health, highlights his…

7:41

A Second Chance: How New AML Treatments Changed Shelley’s Life

AML Clinical Content Hub

In the video, Shelley, a 70-year-old diagnosed with acute myeloid leukemia after her chronic myelomonocytic leukemia progressed, shares her cancer journey and how participating in a clinical trial…

2:56

Components of Risk Stratification in AML

AML Content Hub

An animation from #KnowAML provides a brief overview of risk stratification.

5:47

Combination Magrolimab and Azacitidine as a Frontline Therapy for TP53-Mutated Acute Myeloid Leukemia

AML Content Hub

Naval Daver, MD, University of Texas MD Anderson Cancer Center, shares recent work on combination magrolimab, a CD47-targeting monoclonal antibody, and the hypomethylating agent azacitidine. The azacitidine and…

24:16

Immune Correlates of TP53 Mutational Status in Acute Myeloid Leukemia

AML Content Hub

Sergio Rutella, MD, PhD, FRCPath, hematologist and professor of cancer immunotherapy at the John van Geest Cancer Research Centre, reports new findings from his work on acute myeloid…

23:03

Diagnostic Principles for TP53-Mutant AML

AML Content Hub

@JoeKhouryMD of @MDAndersonNews discusses #diagnosis of #AML with TP53 #mutations.

ASH Releases Evidence-Based Guidelines for Treating Older Patients With AML

AML Content Hub

The American Society of Hematology (ASH) has released 2020 guidelines for treating newly diagnosed acute myeloid leukemia (AML) in older adults. Specifically, the guidelines help patients and doctors…

1:11:42

AML Treatment Update

AML Content Hub

What are the latest treatment options for patients with #AML? @manosnikolousis discusses treatment options with a clinical nurse specialist and a patient with AML.

Expansion of AML Treatment Landscape Underscores Importance of Molecular Testing

AML Content Hub

In this interview, Yousef Zakharia, MD, shares thoughts on the topic of expanding acute myeloid leukemia (AML) treatment. Dr. Zakharia discusses up-to-date AML treatments from combination trials such…

3:56

The Impact of Genetics on Treatment for Patients With MDS

AML Content Hub

Valeria Santini, MD, University of Florence, Italy, discusses the #genomiclandscape of #MDS.

1:33

Treating Secondary AML After HMAs

AML Content Hub

Eunice S. Wang, MD, Roswell Park Comprehensive Cancer Center, Buffalo, New York, discusses the treatment strategies for patients who develop secondary acute myeloid leukemia (AML) following hypomethylating agent…

12:27

Evolving Role of Menin Inhibitors in AML

AML Content Hub

Naval Daver, MD, The University of Texas MD Anderson Cancer Center, Houston, TX; Joshua Zeidner, MD, UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC; Eytan Stein, MD, Memorial…

16:14

New Strategies for TP53-Mutated AML

AML Content Hub

In this panel discussion from the 7th International Workshop on Acute Leukemias, Eunice Wang, MD, Roswell Park Comprehensive Cancer Center, Buffalo, NY; Andrew Wei, MBBS, PhD, Peter MacCallum…

48:17

Webinar: Best Practices in the Management of Acute Myeloid Leukemia

AML Content Hub

In this “Practice Pearls” webinar hosted by Pharmacy Times, expert panelists discuss important topics regarding the treatment of patients with acute myeloid leukemia (AML). Panelists: Katie Culos, PharmD,…

3:05

Michael Savona, MD, Discusses Outcomes From the ASCERTAIN Trial Presented at ASH 2020

AML Content Hub

Phase 3 ASCERTAIN Trial Shows Promising Results with Oral Decitabine and Cedazuridine Combination for the Treatment of Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia

3:55

Targeted Therapy for Acute Myeloid Leukemia

AML Content Hub

Can targeted therapies offer safer and more efficient means to treat patients with acute myeloid leukemia (AML)? Eunice Wang, MD, Chief of the Leukemia Service at Roswell Park…

2:37

Targeting FLT3 in AML

AML Content Hub

Naval G. Daver, MD, a professor and director of the Leukemia Research Alliance Program, The University of Texas MD Anderson Cancer Center, Houston, Texas, discusses the significant advancements…

2:37

How to Manage Patients Progression From MDS to AML

AML Content Hub

Andrew M. Brunner, MD, from @MGHMedicine, discusses #management of #progression from #MDS to #AML.

1:16

CAR T-Cell Therapy Evolves in Leukemia Treatment Landscape

AML Content Hub

Jae H. Park, MD, hematologic oncologist and attending physician at the Leukemia Service and Cellular Therapeutics Center of Memorial Sloan Kettering Cancer Center, discusses the future of chimeric…

20:26

Guidelines for R/R AML Management

AML Content Hub

In this episode of The AML Expert Series, Amer Zeidan, MBBS, Yale School of Medicine, New Haven, Connecticut, and Eunice S. Wang, MD, Roswell Park Comprehensive Cancer Center,…

4:17

Oral Azacitidine Maintenance in AML

AML Content Hub

Fatima Tuz Zahra, MD, a hematology/oncology fellow at Moffitt Cancer Center, University of South Florida, Tampa, presented real-world data from a retrospective study evaluating the effectiveness of oral…

1:25

Expert Explores Potential Role of Doublets and Triplets in IDH1-Mutant Acute Myeloid Leukemia

AML Content Hub

Courtney D. DiNardo, MD, clinical researcher in the Department of Leukemia, Division of Cancer Medicine at the University of Texas MD Anderson Cancer Center, discusses how potential doublet…

1:39

Acute Myeloid Leukemia Practice Pearls: Key Points in Pathway Identification

AML Content Hub

In this “Practice Pearls” roundtable organized by Pharmacy Times, expert panelists discuss acute myeloid leukemia (AML) diagnosis and the various factors affecting decision-making for specialists treating patients with…

:57

Induction Therapy Strategies for Treatment-Related AML

AML Clinical Content Hub

Tara Lin, MD, University of Kansas Medical Center, Kansas City, Kansas, discusses how she approaches choosing induction therapy for patients with treatment-related acute myeloid leukemia, emphasizing that fitness…

59:33

How AML Testing Guides Care

AML Content Hub

Stephen Strickland, MD, Sarah Cannon Research Institute, AML patient and neurologist Dr Joseph, and patient advocate Steve Buechler discuss the critical role of molecular and genetic testing in…

1:43

Considerations for the Management of IDH-Mutated AML

AML Content Hub

Jennifer Marvin-Peek, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses practical considerations for treating patients with IDH-mutated acute myeloid leukemia. Dr Marvin-Peek highlights the…

1:18

Dr. Daver on the Advancing Treatment Landscape in AML

AML Content Hub

Naval G. Daver, MD, an associate professor in the Department of Leukemia, Division of Cancer Medicine at the University of Texas MD Anderson Cancer Center, highlights findings from the randomized phase…

2:22

Choosing Donors for alloSCT in Secondary AML

AML Content Hub

In this expert interview, Arnon Nagler, MD, Chaim Sheba Medical Center, Tel-Aviv, Israel, discusses donor selection for allogeneic stem cell transplantation in secondary acute myeloid leukemia (AML) patients…

18:28

AML Treatment Challenges Who, When, and How

AML Content Hub

Jorge Cortes, MD, director of the Georgia Cancer Center in Augusta, GA, provides a comprehensive look at the current challenges specialists face in providing optimal treatment for patients…

26:41

Treatment Strategies for Therapy-Related and De Novo AML

AML Clinical Content Hub

In this Oncology Brothers podcast episode, Naval Daver, MD, MD Anderson Cancer Center, Houston, Texas, discusses treatment strategies for both therapy‑related and de novo acute myeloid leukemia (AML), focusing on cases…

1:35

Exploring the Data for AML Treated With Magrolimab and Azacitidine

AML Content Hub

Naval G. Daver, MD, associate professor in the Department of Leukemia at The University of Texas MD Anderson Cancer Center, explains the results of a phase 1 trial…

4:49

AML Treatment for Unfit Patients

AML Content Hub

Andrius Žučenka, MD, Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania, discusses the challenges and advancements in treating acute myeloid leukemia (AML) in patients who are unfit for intensive…

1:01

Treating Extramedullary AML

AML Content Hub

Cristina Papayannidis, MD, PhD, University of Bologna, Bologna, Italy, discusses a study evaluating the efficacy of combining venetoclax with hypomethylating agents in treating patients with acute myeloid leukemia…

Round Two: Long Term Complications in Adolescent and Young Adult Acute Myeloid Leukemia Survivors

AML Content Hub

Researchers from UC Davis Comprehensive Cancer Center discuss results from their recent study on long term complications adolescents and young adults face after treatment for acute myeloid leukemia…

1:49

Azacitadine Plus Pevonedistat Shows Efficacy in MDS/CMML or LB AML

AML Content Hub

Mikkael Sekeres, MD, director of the Leukemia Program and vice-chair for Clinical Research at the Cleveland Clinic Taussig Cancer Institute, discusses a phase 2 study of pevonedistat plus azacitidine…